Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC With Mitomycin-C After Complete Cytoreduction in Colon Cancer Peritoneal Metastases
2024-512726-28-00Phase 4Authorised
- Sponsor
- Hospital Universitario de Fuenlabrada
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitomycin c in colorectal cancer (CRC), sponsored by Hospital Universitario de Fuenlabrada. Primary endpoint: Peritoneal recurrence-free survival at 1, 2 and 3 years. Planned start May 2024; status: authorised.
02
Drugs
mitomycin c
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-512726-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512726-28-00.